Dr. Dolloff is Founder and Chief Scientific Officer of Leukogene Therapeutics, Inc. (LTI). LTI has exclusive licenses to develop intellectual property (IP) that originated in his lab at the Medical University of South Carolina (MUSC) in Charleston, SC. Dr. Dolloff has 15+ years of drug discovery experience and is inventor on multiple patents. He runs a fully-funded academic lab at MUSC. As CSO of LTI, he has secured over $3MM in company funding from the NCI, the SC Research Authority, and private investors to fund the development of a new class of protein disulfide isomerase inhibitor for the treatment of various solid and hematological malignancies.